120 related articles for article (PubMed ID: 313322)
1. Immunologic changes in regional lymph nodes of melanoma patients.
Hammer C; Lewis MG; Rowden G; Phillips T
Chir Forum Exp Klin Forsch; 1978; (1978):235-8. PubMed ID: 313322
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of T- and B-cell immunity of regional lymph nodes in patients with skin melanoma and prognosis of the disease].
Serov AA; Kadagidze ZG
Vopr Onkol; 1983; 29(12):18-20. PubMed ID: 6607569
[TBL] [Abstract][Full Text] [Related]
3. [Assessment of the immunohistological state of the lymph nodes regional to a tumor].
Serov AA
Biull Eksp Biol Med; 1980 Feb; 89(2):196-8. PubMed ID: 6966167
[TBL] [Abstract][Full Text] [Related]
4. [Effect of Ulceration and lymph node metastasis of skin melanomas on the germinal centers of regional lymph nodes].
Weidner F; Schroll S; Schönberger A; Hornstein OP
Pathologe; 1982 Jul; 3(4):184-7. PubMed ID: 6981109
[No Abstract] [Full Text] [Related]
5. Membrane markers of lymphocytes in lymphomas, melanoma and lupus erythematosus.
Edelson RL
Int J Dermatol; 1976 Oct; 15(8):577-86. PubMed ID: 786913
[No Abstract] [Full Text] [Related]
6. [Immunology of melanoma].
Vanwijck R; Bernheim JL; Lejeune FJ
Acta Chir Belg; 1974 Mar; 73(2):135-88. PubMed ID: 4615541
[No Abstract] [Full Text] [Related]
7. Studies of humoral and cell-mediated immunity in human melanoma.
Mukherji B; Nathanson L; Clark DA
Yale J Biol Med; 1973 Dec; 46(5):681-92. PubMed ID: 4130586
[No Abstract] [Full Text] [Related]
8. T Cells Derived From Human Melanoma Draining Lymph Nodes Mediate Melanoma-specific Antitumor Responses In Vitro and In Vivo in Human Melanoma Xenograft Model.
Zhang M; Graor H; Visioni A; Strohl M; Yan L; Caja K; Kim JA
J Immunother; 2015; 38(6):229-38. PubMed ID: 26049546
[TBL] [Abstract][Full Text] [Related]
9. Melanoma cytoplasmic humoral antibody test. A diagnostic adjunct.
Copeman PW; Elliott PG
Br J Dermatol; 1976 May; 94(5):565-8. PubMed ID: 773408
[TBL] [Abstract][Full Text] [Related]
10. Regional lymphatic immunity in melanoma.
Grotz TE; Mansfield AS; Jakub JW; Markovic SN
Melanoma Res; 2012 Feb; 22(1):9-18. PubMed ID: 22082957
[TBL] [Abstract][Full Text] [Related]
11. Epidermal cytoplasmic antibodies: incidence and type in normal persons and patients with melanoma.
Abel EA; Bystryn JC
J Invest Dermatol; 1976 Jan; 66(1):44-8. PubMed ID: 1107434
[TBL] [Abstract][Full Text] [Related]
12. The immune response in human malignant melanoma.
Mackie RM
Clin Exp Dermatol; 1976 Mar; 1(1):23-8. PubMed ID: 773575
[No Abstract] [Full Text] [Related]
13. Separation of two distinct tumor-associated antibodies in the serum of melanoma patients.
Lewis MG; Phillips TM
J Natl Cancer Inst; 1972 Sep; 49(3):915-7. PubMed ID: 4630549
[No Abstract] [Full Text] [Related]
14. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients.
Verdijk P; Aarntzen EH; Lesterhuis WJ; Boullart AC; Kok E; van Rossum MM; Strijk S; Eijckeler F; Bonenkamp JJ; Jacobs JF; Blokx W; Vankrieken JH; Joosten I; Boerman OC; Oyen WJ; Adema G; Punt CJ; Figdor CG; de Vries IJ
Clin Cancer Res; 2009 Apr; 15(7):2531-40. PubMed ID: 19318472
[TBL] [Abstract][Full Text] [Related]
15. Report of the immunology working party of the EORTC melanoma group.
Rümke P
Eur J Cancer Clin Oncol; 1981 Jul; 17(7):839-41. PubMed ID: 7037425
[No Abstract] [Full Text] [Related]
16. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
Seigler HF; Shingleton WW; Pickrell KL
Plast Reconstr Surg; 1975 Mar; 55(3):294-8. PubMed ID: 1118487
[TBL] [Abstract][Full Text] [Related]
17. Humoral immune response in melanoma and glioma patients: a solubilized melanoma-membrane component as a tool for detecting circulating antibodies.
Birkmayer GD
Cancer; 1981 Dec; 48(11):2399-408. PubMed ID: 7296490
[TBL] [Abstract][Full Text] [Related]
18. [Immunological characteristics of malignant skin lymphomas].
Shaposhnikov OK; Rodionov AN
Vestn Dermatol Venerol; 1982 Mar; (3):4-11. PubMed ID: 6978580
[No Abstract] [Full Text] [Related]
19. Immune derangement in patients with malignant melanoma.
Lewis MG; Phillips TM; Noble PB; Hartmann DP
J Cutan Pathol; 1979 Jun; 6(3):201-7. PubMed ID: 479438
[TBL] [Abstract][Full Text] [Related]
20. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.
Jones RC; Kelley M; Gupta RK; Nizze JA; Yee R; Leopoldo Z; Qi K; Stern S; Morton DL
Ann Surg Oncol; 1996 Sep; 3(5):437-45. PubMed ID: 8876885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
